RemeGen Co. Ltd. A (688331.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005B03

Price
95.80 CNY
Market cap
52.62 bn CNY
P/E (2025)
74.26
P/S (2025)
16.18
Dividend yield
0.00 %
Net margin
21.79 %
Return on equity (ROE)
–
Return on assets (ROA)
9.78 %

RemeGen Co. Ltd. A financials

Fiscal year20242025
Revenue1.72 bn CNY3.25 bn CNY
Gross profit1.37 bn CNY3.25 bn CNY
Operating income-1.46 bn CNY721.43 m CNY
EBIT-1.40 bn CNY709.27 m CNY
Net income-1.47 bn CNY708.52 m CNY
Diluted EPS – continuing operations-2.73 CNY1.29 CNY

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About RemeGen Co. Ltd. A

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.

RemeGen Co. Ltd. A stock (688331.SS): P/E, revenue, dividend | finmetric